Marshall Posner

I am a Father Grandfather. I am a physician for patients with head and neck cancer, giving them the best care through empathy research and innovation.

[Mount Sinai Tisch Cancer Center @TischCancer]

From @marshposnermd and colleagues: Quality of Life Analysis of HPV-Positive Oropharyngeal Cancer Patients in a Randomized Trial of Reduced-Dose Versus Standard Chemoradiotherapy: 5-Year Follow-Up https://t.co/phqwY8ehyP @IcahnMountSinai

[Marshall Posner @marshposnermd]

Great work on Omicron, very reassuring- if you are boosted! Death rates are still too high for this to be as benign as the common cold and impact on children still unknown.

https://t.co/wU6rP9feoB

[Marshall Posner @marshposnermd]

@DrNabilSaba Totally agree that this should be SOC. It is a major failure that CTEP has not done a real dose de-escalation trial. 3311 and SIRS show the way. our editorial addresses this.
https://t.co/gjXGzPX8QF

[Marshall Posner @marshposnermd]

@KarynAGoodman Congratulations Karyn

[VJ Oncology @VJOncology]

👨‍⚕️ @marshposnermd of @TischCancer discusses the quality of life of HPV+ oropharyngeal cancer patients receiving chemoradiotherapy 📣

🎥 Watch here: 👉https://t.co/ZabSyBuQEL👈

@VJOncology @ASCO @OncoAlert #ASCO21 #HNCsm #Oncology #RadOnc

[Mount Sinai Tisch Cancer Center @TischCancer]

Welcome to Dr. Joseph A. Sparano, Mount Sinai's new Chief of Hematology and Medical Oncology and Deputy Director of The Tisch Cancer Institute.
https://t.co/iS247GyVvU
@jsparano @IcahnMountSinai @MountSinaiNYC

[Mount Sinai Health System @MountSinaiNYC]

.@marshposnermd shares his #ASCO21 presentation on survival and progression-free survival results after induction #chemotherapy followed by de-escalated chemoradiotherapy for locally advanced HPV positive oropharynx cancer.

[Mount Sinai Health System @MountSinaiNYC]

#ASCO21 Poster Session by @marshposnermd: Survival and progression-free survival results after induction chemotherapy followed by de-escalated chemoradiotherapy for locally advanced HPV positive oropharynx #cancer: https://t.co/nJfN63QVrV @ASCO @TischCancer

[Marshall Posner @marshposnermd]

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma | NEJM https://t.co/jRCgLMyLXj Kudos to Matt and the team, a significant step forward!!

[Marshall Posner @marshposnermd]

Great work Matt and Team #thisisteamscience

[Marshall Posner @marshposnermd]

Here is our article on surgery and risk based de-escalation of radiation in HPV Oropharynx Ca. Spectacular results - https://t.co/3dOJVUAzjA

[Marshall Posner @marshposnermd]

Proud to be a part of this amazing work with Ross at Mount Sinai: https://t.co/fswMa88tBM